US OptionsDetailed Quotes

IFRX240719C5000

Watchlist

0.10
0.000.00%

15min DelayClose Feb 20 11:28 ET

0.00High0.00Low

InflaRx Stock Discussion

Stock Region

Jun 25 18:40

Biopharmaceutical Company Selected By BARDA For Novel ARDS Treatment

InflaRx's GOHIBIC (Vilobelimab) Included in BARDA-Sponsored Clinical Trial for Acute Respiratory Distress Syndrome (ARDS).
InflaRx N.V., a biopharmaceutical company specializing in anti-inflammatory treatments through targeting the complement system, announced that its investigational drug GOHIBIC (vilobelimab) has been chosen by the Biomedical Advanced Research and Development Authority (BARDA). This selection places vilobelima...

Jaguar8

May 21 13:38

$InflaRx(IFRX.US)$
NEWS
InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators

10k profit daily

Jan 9 10:23

$InflaRx(IFRX.US)$ getting interesting phase 1 went good

wooper

Nov 3, 2023 08:35

I like pstv only

📈💥 Let's seize Friday! Yesterday we witnessed a ticker surge with a 44.24% LONG MOVE. Today's focus:
✅1️⃣ HOWL Long > 2.73 Short < 2.61
✅2️⃣ NVOS Long > 0.3300 Short < 0.3095
✅3️⃣ CYTO Long > 0.2035 Short < 0.1855
✅4️⃣ PSTV Long > 1.64 Short < 1.49
✅5️⃣ IFRX Long > 1.62 Short < 1.53
✅6️⃣ FUBO Long > 3.20 Short < 2.99

$InflaRx(IFRX.US)$ 👀

ColumnsWeekly FDA Drug Pipeline Calendar (April 10 - April 14)

Hello mooers, welcome to another week of the FDA calendar. Here are what happened last week and what's coming up this week.
BIGGEST MOVERS FROM THIS WEEK
The FDA has granted Emergency Use Authorization (EUA) for Gohibic (vilobelimab) to $InflaRx(IFRX.US)$ for the treatment of COVID-19 in hospitalized adults, provided it is initiated within 48 hours of receiving invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (E...